Related Experiment Videos
AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia
Medical and Pediatric Oncology
|January 1, 1984
Abstract:
27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA. Three achieved a complete remission, and two a partial remission. Median survival for all patients was 12 weeks and was 16 weeks for responders.